JP6240072B2 - シクロスポリン誘導体 - Google Patents
シクロスポリン誘導体 Download PDFInfo
- Publication number
- JP6240072B2 JP6240072B2 JP2014527635A JP2014527635A JP6240072B2 JP 6240072 B2 JP6240072 B2 JP 6240072B2 JP 2014527635 A JP2014527635 A JP 2014527635A JP 2014527635 A JP2014527635 A JP 2014527635A JP 6240072 B2 JP6240072 B2 JP 6240072B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- och
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011111991A DE102011111991A1 (de) | 2011-08-30 | 2011-08-30 | Neue Cyclosporin-Derivate |
| DE102011111991.8 | 2011-08-30 | ||
| PCT/EP2012/066726 WO2013030208A1 (de) | 2011-08-30 | 2012-08-29 | Cyclosporin-derivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531417A JP2014531417A (ja) | 2014-11-27 |
| JP2014531417A5 JP2014531417A5 (cg-RX-API-DMAC7.html) | 2017-01-19 |
| JP6240072B2 true JP6240072B2 (ja) | 2017-11-29 |
Family
ID=46754993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527635A Expired - Fee Related JP6240072B2 (ja) | 2011-08-30 | 2012-08-29 | シクロスポリン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9453051B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2751127B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6240072B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103842372A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012300934B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2845663C (cg-RX-API-DMAC7.html) |
| DE (1) | DE102011111991A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2601029T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013030208A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0737730Y2 (ja) | 1989-10-04 | 1995-08-30 | 横河電機株式会社 | 溶射装置 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| CN104513296B (zh) * | 2013-09-27 | 2018-03-02 | 王喆明 | 一种环肽化合物及其用途 |
| WO2016112295A1 (en) | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| CA3000822A1 (en) * | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CA3020594A1 (en) | 2016-04-12 | 2017-10-19 | Warp Drive Bio, Inc. | Compositions and methods for the production of compounds |
| US12594275B2 (en) | 2019-02-07 | 2026-04-07 | The Regents Of The University Of California | Immunophilin binding agents and uses thereof |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021173474A1 (en) * | 2020-02-26 | 2021-09-02 | Bacainn Biotherapeutics, Ltd. | Cyclosporine compositions and methods of use |
| CA3172535A1 (en) * | 2020-03-26 | 2021-09-30 | Ching-Pong Mak | Cyclophilin inhibitors and uses thereof |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| WO2022192716A1 (en) * | 2021-03-11 | 2022-09-15 | Massachusetts Institute Of Technology | Small molecule suppressors of apoe gene expression and cerebral vascular amyloid pathology |
| CN112919984B (zh) * | 2021-04-16 | 2022-03-08 | 安徽硒无忧现代农业科技有限公司 | 一种生态化富硒有机营养液及其制备方法 |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1506200A (en) * | 1975-04-30 | 1978-04-05 | Farmaceutici Italia | Glycosides |
| US4672044A (en) | 1984-08-24 | 1987-06-09 | Scripps Clinic & Research Foundation | Murine monoclonal antibody combining site to human C3b receptor (CR1) |
| GB8426672D0 (en) * | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| US4798823A (en) * | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
| AT401823B (de) | 1993-09-30 | 1996-12-27 | Avl Verbrennungskraft Messtech | Optischer indikator zur bestimmung der aktivität eines ions in einer probe |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| PT848009E (pt) * | 1996-12-16 | 2000-11-30 | Pharmachemie Bv | Processo para a preparacao de epirubicina ou seus sais de adicao de acido a partir de daunorubicina |
| CA2285454A1 (en) | 1997-04-07 | 1998-10-15 | Axys Pharmaceuticals Corporation | Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity |
| FR2762843B1 (fr) * | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| DE69832984T2 (de) | 1997-10-08 | 2006-09-21 | Isotechnika, Inc., Edmonton | DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN |
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| WO2000020400A1 (en) | 1998-10-05 | 2000-04-13 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
| DE19859910C2 (de) | 1998-12-23 | 2001-03-22 | Ratiopharm Gmbh | Orales Arzneimittel |
| IL135884A (en) | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
| US6596499B2 (en) | 2000-11-30 | 2003-07-22 | The Netherlands Cancer Institute | Membrane molecule indicator compositions and methods |
| US6784156B2 (en) * | 2001-03-05 | 2004-08-31 | Enanta Pharmaceuticals, Inc. | Cyclosporins for the treatment of respiratory diseases |
| WO2003087089A1 (en) | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| AU2003285958A1 (en) | 2002-10-25 | 2004-05-25 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
| WO2005004805A2 (en) * | 2003-07-02 | 2005-01-20 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| US20090099346A1 (en) * | 2003-07-02 | 2009-04-16 | Victor Matvienko | Thermally stable crystalline epirubicin hydrochloride |
| DE10339597A1 (de) | 2003-08-26 | 2005-03-31 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zum Nachweis biochemischer Aktivität enthaltend Gap Junctions |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7378391B2 (en) * | 2004-09-29 | 2008-05-27 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| DE102006038403A1 (de) | 2006-08-17 | 2008-02-21 | Heinrich-Heine-Universität Düsseldorf | Verwendung bestimmter chemischer Verbindungen zur Inhibierung der Peptidyl-Prolyl-cis/trans-Isomeraseaktivität von Cyclophilinen |
| SG144809A1 (en) | 2007-01-11 | 2008-08-28 | Millipore U K Ltd | Benzimidazole compounds and their use as chromatographic ligands |
| PL1990405T3 (pl) * | 2007-05-08 | 2018-01-31 | Provivo Oy | Genetycznie zmodyfikowane szczepy wytwarzające metabolity będące antracyklinami użyteczne jako leki przeciwnowotworowe |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| MX2011001152A (es) | 2008-07-30 | 2011-06-09 | Isotechnika Pharma Inc | Moleculas de analogo de ciclosporina no-inmunesupresoras. |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| US8481483B2 (en) * | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| DE102009037551A1 (de) | 2009-08-17 | 2011-02-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Cyclosporinderivate |
-
2011
- 2011-08-30 DE DE102011111991A patent/DE102011111991A1/de not_active Ceased
-
2012
- 2012-08-29 WO PCT/EP2012/066726 patent/WO2013030208A1/de not_active Ceased
- 2012-08-29 US US14/241,126 patent/US9453051B2/en active Active
- 2012-08-29 CA CA2845663A patent/CA2845663C/en active Active
- 2012-08-29 AU AU2012300934A patent/AU2012300934B2/en not_active Ceased
- 2012-08-29 EP EP12751509.6A patent/EP2751127B1/de active Active
- 2012-08-29 ES ES12751509.6T patent/ES2601029T3/es active Active
- 2012-08-29 JP JP2014527635A patent/JP6240072B2/ja not_active Expired - Fee Related
- 2012-08-29 CN CN201280042682.1A patent/CN103842372A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0737730Y2 (ja) | 1989-10-04 | 1995-08-30 | 横河電機株式会社 | 溶射装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2601029T3 (es) | 2017-02-14 |
| WO2013030208A1 (de) | 2013-03-07 |
| EP2751127B1 (de) | 2016-07-27 |
| CA2845663A1 (en) | 2013-03-07 |
| AU2012300934B2 (en) | 2016-06-09 |
| AU2012300934A1 (en) | 2014-03-13 |
| EP2751127A1 (de) | 2014-07-09 |
| US9453051B2 (en) | 2016-09-27 |
| CA2845663C (en) | 2020-09-08 |
| DE102011111991A1 (de) | 2013-02-28 |
| CN103842372A (zh) | 2014-06-04 |
| JP2014531417A (ja) | 2014-11-27 |
| US20140316104A1 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531417A (ja) | シクロスポリン誘導体 | |
| JP6785932B2 (ja) | 構築されたポリペプチド特異性のモジュレーション | |
| Li et al. | Genetically encoded alkenyl–pyrrolysine analogues for thiol–ene reaction mediated site-specific protein labeling | |
| JP6571650B2 (ja) | アミノ酸誘導体 | |
| RU2192421C2 (ru) | Производные изоксазола и амида кротоновой кислоты | |
| CN107952080A (zh) | 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用 | |
| WO2023227133A1 (zh) | 人胰淀素类似物、其衍生物及用途 | |
| TW202504632A (zh) | 靶向磷脂醯肌醇蛋白聚糖-3之肽組成物及其用途 | |
| TW202304947A (zh) | 胜肽及包含胜肽之組成物 | |
| CN114890990B (zh) | 一种化合物及在制备nampt蛋白自噬降解剂中的应用 | |
| TW202334179A (zh) | 胜肽 | |
| WO2021056754A1 (zh) | 一种酸法制备抗体药物偶联物中间体的方法及其应用 | |
| Noden et al. | Total synthesis of Paenibacterin and its analogues | |
| WO2016192149A1 (zh) | 一类双烷氧酰胺烷基阳离子肽脂质及其合成方法和应用 | |
| CN110294793A (zh) | Sumo荧光探针及其制备方法 | |
| TW202321274A (zh) | 人類運鐵蛋白受體結合肽 | |
| WO2023048236A1 (ja) | ペプチド | |
| HK1195916A (en) | Cyclosporin derivatives | |
| WO2010043046A1 (en) | Peptide inhibitors of type iii secretion | |
| CN114507270B (zh) | 一种靶向pd-l1多肽、制备方法,组装形成的纳米管及应用 | |
| US20260049107A1 (en) | Artificial viral capsid | |
| AU2017255938B2 (en) | Unusual substrates of tubulin tyrosine ligase | |
| TW202426031A (zh) | EphA2結合待定肽及包含其之組成物 | |
| HK40105341A (en) | Human transferrin receptor–binding peptide | |
| Peschke et al. | Controlled coupling of peptides at their C-termini |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150828 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161004 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20161129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170314 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170908 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171003 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171102 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6240072 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |